

CONTENTS

Title	Page No.
Abstract	<i>i-iii</i>
List of abbreviations	<i>iv-vii</i>
List of figures	<i>viii-xv</i>
List of schemes	<i>xvi</i>
List of tables	<i>xvii-xix</i>
Preface	<i>xx-xxii</i>
Chapter 1. INTRODUCTION	1-33
1.1. Neurodegenerative diseases: biggest challenge of present century	1-3
1.2. Strategies employed for anti-neurodegenerative drug discovery	3-6
1.2.1. MTDL approach	4-5
1.2.2. Rational design strategies for MTDL	5-6
1.2.3. MTDLs and NDDs	6
1.3. Monoamine oxidases: an overview	6-21
1.3.1. Molecular characteristics of MAO	7-9
1.3.2. Role of MAO in neurodegeneration	9-11
1.3.3. Three dimensional structure of MAO	12-16
1.3.3.1. Crystal structure of human MAO-A	12-13
1.3.3.2. Crystal structure of human MAO-B	13-15
1.3.3.3. Flavin binding domain	15-16
1.3.4. Monoamine oxidase inhibitors	17-21
1.3.4.1. Mode of action of MAOIs	20
1.3.4.2. Adverse effects of MAOIs	20-21
1.4. Acetylcholinesterase: an overview	21-31
1.4.1. Molecular characteristics of AChE	21-22

1.4.2. Role of AChE in neurodegeneration	22-24
1.4.3. Three dimensional structure of AChE	24-29
1.4.3.1. Crystal structure of human AChE	25-26
1.4.3.2. Active site of AChE	26-28
1.4.3.3. Peripheral anionic site	28-29
1.4.3.4. Mechanism of action of catalytic triad	29
1.4.4. Clinically approved AChE inhibitors	29-31
1.4.4.1. Mode of action of AChE inhibitors in NDDs	30-31
1.4.4.2. Adverse effects of AChE inhibitors	31
1.5. Recent advances in the discovery of anti-neurodegenerative agents	31-33
1.6. Conclusion	33
Chapter 2. LITERATURE REVIEW	34-73
2.1. Review on hydrazones	34-39
2.1.1. Chemical review on hydrazones	35-36
2.1.2. Biological review on hydrazones	36-39
2.2. Review on semicarbazones	40-46
2.2.1. Chemical review on semicarbazones	40-42
2.2.2. Biological review on semicarbazones	42-46
2.3. Review on isatin	46-52
2.3.1. Occurrence of isatin	47
2.3.2. Chemical review on isatin and its derivatives	47-48
2.3.3. Biological review on isatin and its derivatives	48-52
2.4. Review on thiazole	52-56
2.4.1. Chemical review on thiazole	52-53
2.4.2. Occurrence of thiazole and thiazolium salts	53
2.4.3. Biological review on thiazole and its derivatives	53-56

2.5. Review on benzothiazole (BTA)	56-61
2.5.1. Occurrence of BTA	57-58
2.5.2. Chemical review on BTA	58-59
2.5.3. Biological review on BTA and its derivatives	59-61
2.6. Review on 1,3-benzodioxole	61-68
2.6.1. Chemical review on 1,3-benzodioxole	62
2.6.2. Biological review on 1,3-benzodioxole derivatives	62-68
2.7. Review on multi-target-directed ligand (MTDL) approach towards the discovery of anti-neurodegenerative agents	68-73
2.7.1. MTDLs targeting MAO and AChE	68-70
2.7.2. MTDLs targeting MAO and iron	70-71
2.7.3. MTDLs targeting MAO, AChE and iron	71-73
Chapter 3. RATIONALE, OBJECTIVES AND PLAN OF WORK	74-89
3.1. Rationale	74-81
3.1.1. Drug discovery strategies for NDDs	74-75
3.1.1.1. Classical approach	74
3.1.1.2. Multi-target-directed ligand (MTDL) approach	75
3.1.2. Pharmacophore and its role in drug design	75-77
3.1.2.1. Introduction to pharmacophore (PCP)	75-76
3.1.2.2. Definition	76-77
3.1.2.3. Role of PCP in drug design	77
3.1.3. Development of pharmacophore for MAOIs	77-79
3.1.4. Development of pharmacophore for AChE inhibitors	79
3.1.5. Hybrid PCP features in MTDLs targeting dual MAO and AChE inhibition	79-80
3.2. Objectives of the present study	80
3.3. Design of chemical library	81-89

3.3.1. Design of 2-amino-6-nitrobenzothiazole derived extended hydrazones (BTA library)	83-84
3.3.2. Design of 2-amino-5-nitrothiazole derived semicarbazones (NTA library)	84-85
3.3.3. Design of 3,4-(methylenedioxy)aniline derived semicarbazones (MDA library)	86-87
3.3.4. Design of 3-hydroxy-3-substituted oxindole analogues of isatin (HPO library)	87-88
3.4. Plan of work	88-89
Chapter 4. EXPERIMENTAL WORK	
	90-205
4.1. 2-Amino-6-nitrobenzothiazole derived extended hydrazones [BTA-1 to BTA-30]	90-143
4.1.1. Synthesis	90-96
4.1.1.1. Chemicals and reagents	90
4.1.1.2. Synthetic protocol	90-96
4.1.1.3. Reaction mechanism	93-94
4.1.2. Characterization	96-130
4.1.2.1. Physicochemical characterization	96-100
4.1.2.2. Spectral characterization and elemental analysis	100-102
4.1.2.3. Spectral characterization and elemental analysis data of intermediates (BTE and BTH) and final compounds (BTA-1 to BTA-30)	102-130
4.1.3. Biological evaluation	130-143
4.1.3.1. Monoamine oxidase (MAO) enzyme inhibition studies	130-135
4.1.3.2. Acetylcholinesterase (AChE) enzyme inhibition studies	135-138
4.1.3.3. Behavioural studies	138-140
4.1.3.4. Neurotoxicity screening (Rota rod test)	140
4.1.3.5. Antioxidant activity (DPPH radical scavenging assay)	141
4.1.3.6. Assessment of liver function	142
4.1.4. <i>In-silico</i> molecular property analysis and ADMET prediction	142-143

studies	
4.2. 2-Amino-5-nitrothiazole derived semicarbazones [NTA-1 to NTA-18]	144-166
4.2.1. Synthesis	144-147
4.2.1.1. Chemicals and reagents	144
4.2.1.2. Synthetic protocol	144-147
4.2.1.3. Reaction mechanism	145-146
4.2.2. Characterization	147-166
4.2.2.1. Physicochemical characterization	147-148
4.2.2.2. Spectral characterization and elemental analysis	148
4.2.2.3. Spectral characterization and elemental analysis data of intermediates (NTU and NTS) and final compounds (NTA-1 to NTA-18)	148-165
4.2.3. Biological evaluation	166
4.2.4. <i>In-silico</i> molecular property analysis and ADMET prediction studies	166
4.3. 3,4-(Methylenedioxy)aniline derived semicarbazones [MDA-1 to MDA-14]	167-187
4.3.1. Synthesis	167-169
4.3.1.1. Chemicals and reagents	167
4.3.1.2. Synthetic protocol	167-169
4.3.2. Characterization	169-187
4.3.2.1. Physicochemical characterization	169-170
4.3.2.2. Spectral characterization and elemental analysis	170
4.3.2.3. Spectral characterization and elemental analysis data of intermediates (MDU and MDS) and final compounds (MDA-1 to MDA-14)	170-187
4.3.3. Biological evaluation	187
4.3.4. <i>In-silico</i> molecular property analysis and ADMET prediction studies	187
4.4. 3-Hydroxy-3-substituted oxindole analogues of isatin [HPO-1 to HPO-18]	188-205

HPO-14]	
4.4.1. Synthesis	188-191
4.4.1.1. Chemicals and reagents	188
4.4.1.2. Synthetic protocol	188-191
4.4.1.3. Reaction mechanism	190
4.4.2. Characterization	192-205
4.4.2.1. Physicochemical characterization	192
4.4.2.2. Spectral characterization and elemental analysis	192-193
4.4.2.3. Spectral characterization and elemental analysis data of intermediates (ISN-1) and final compounds (HPO-1 to HPO-14)	193-205
4.4.3. Biological evaluation	205
4.4.4. <i>In-silico</i> molecular property analysis and ADMET prediction studies	205
Chapter 5. RESULTS AND DISCUSSION	206-332
5.1. 2-Amino-6-nitrobenzothiazole derived extended hydrazones [BTA-1 to BTA-30]	206-243
5.1.1. Synthesis	206
5.1.2. Characterization	206-209
5.1.2.1. Physicochemical characterization	206-207
5.1.2.2. Spectral characterization and elemental analysis	207-209
5.1.3. Biological evaluation	209-236
5.1.3.1. MAO enzyme inhibition studies	209-221
5.1.3.2. AChE enzyme inhibition studies	222-230
5.1.3.3. Behavioural studies	230-233
5.1.3.4. Neurotoxicity screening (Rotarod test)	233-234
5.1.3.5. Antioxidant activity	234-235
5.1.3.6. Assessment of liver function	235-236
5.1.4. <i>In-silico</i> molecular property analysis and ADMET prediction	236-243

studies	
5.2. 2-Amino-5-nitrothiazole derived semicarbazones [NTA-1 to NTA-18]	244-274
5.2.1. Synthesis	244
5.2.2. Characterization	244-248
5.2.2.1. Physicochemical characterization	244-245
5.2.2.2. Spectral characterization and elemental analysis	245-247
5.2.3. Biological evaluation	247-269
5.2.3.1. MAO enzyme inhibition studies	247-258
5.2.3.2. AChE enzyme inhibition studies	258-264
5.2.3.3. Behavioural studies	264-266
5.2.3.4. Neurotoxicity screening (Rotarod test)	266-267
5.2.3.5. Antioxidant activity (DPPH radical scavenging assay)	267-268
5.2.3.6. Assessment of liver function	268-269
5.2.4. <i>In-silico</i> molecular property analysis and ADMET prediction studies	269-274
5.3. 3,4-(Methylenedioxy)aniline derived semicarbazones [MDA-1 to MDA-14]	275-302
5.3.1. Synthesis	275
5.3.2. Characterization	275-279
5.3.2.1. Physicochemical characterization	275-276
5.3.2.2. Spectral characterization and elemental analysis	276-278
5.3.3. Biological evaluation	278-298
5.3.3.1. MAO enzyme inhibition studies	278-287
5.3.3.2. AChE enzyme inhibition studies	287-293
5.3.3.3. Behavioural studies	293-295
5.3.3.4. Neurotoxicity screening (Rotarod test)	295-296
5.3.3.5. Antioxidant activity	296

5.3.3.6. Assessment of liver function	297-298
5.3.4. <i>In-silico</i> molecular property analysis and ADMET prediction studies	298-302
5.4. 3-Hydroxy-3-substituted oxindole analogues of isatin [HPO-1 to HPO-14]	303-332
5.4.1. Synthesis	303
5.4.2. Characterization	303-306
5.4.2.1. Physicochemical characterization	303-304
5.4.2.2. Spectral characterization and elemental analysis	304-306
5.4.3. Biological evaluation	306-328
5.4.3.1. MAO enzyme inhibition studies	306-316
5.4.3.2. AChE enzyme inhibition studies	316-323
5.4.3.3. Behavioural studies	323-325
5.4.3.4. Neurotoxicity screening (Rotarod test)	325-326
5.4.3.5. Antioxidant activity	326
5.4.3.6. Assessment of liver function	327-328
5.4.4. <i>In-silico</i> molecular property analysis and ADMET prediction studies	328-332
Chapter 6. SUMMARY AND CONCLUSION	333-343
6.1. Summary	333-342
6.1.1. Summary of MAO inhibition studies	334-338
6.1.1.1. Comparison of lead MAO-B inhibitors across the series (extended hydrazones and semicarbazones)	334-337
6.1.1.2. Comparison of lead MAO-A inhibitors across the series	337-338
6.1.2. Summary of AChE inhibition studies	338-340
6.1.3. Summary of behavioural studies	340-341
6.1.4. Summary of neurotoxicity screening	341
6.1.5. Summary of antioxidant activity studies	341-342

6.1.6. Summary of liver toxicity studies	342
6.2. Conclusions	342-343

BIBLIOGRAPHY

Appendices

Animal Ethical Clearance Certificate

List of publications and presentations